Last reviewed · How we verify
Placebo to Linagliptin
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.
At a glance
| Generic name | Placebo to Linagliptin |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Linagliptin works by blocking the action of DPP-4, an enzyme that breaks down incretin hormones. This leads to an increase in the levels of incretin hormones, which in turn stimulates the release of insulin from the pancreas in a glucose-dependent manner. As a result, blood glucose levels are lowered.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Headache
- Muscle pain
Key clinical trials
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes (PHASE3)
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM (PHASE3)
- Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus (PHASE3)
- HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (PHASE2)
- Linagliptin Add-on to Insulin Background Therapy (PHASE3)
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Linagliptin CI brief — competitive landscape report
- Placebo to Linagliptin updates RSS · CI watch RSS
- LG Life Sciences portfolio CI